Is the Dominican Republic story real, or a tidy origin myth someone wrote later?
The board claim starts in a lab that did not exist yet
Claim on the pink board: finasteride began as a molecule hunt. Label the origin instead as a clinic note that already knew which enzyme to block.
Most origin stories for oral drugs start with a screening deck and a lucky hit. Finasteride does not. Before Merck had a 4-azasteroid in a flask, field endocrinologists already knew what happens when type 2 5-alpha-reductase never works. Infants in isolated Dominican settlements were often raised as girls. At puberty a delayed male pattern arrived - voice, muscle, genital change villagers nicknamed guevedoces, roughly 'penis at twelve.' Folklore until someone mapped the biochemistry.
Julianne Imperato-McGinley published that map in the mid-1970s. Testosterone was present. Conversion to dihydrotestosterone was not. One missing enzyme explained the whole picture, including two adult findings that later became product labels: small prostates and almost no male-pattern balding. That is a target, not a rumor. Strike the idea that chemists invented the question. They inherited it.
What Imperato-McGinley put on paper in 1974
The 1974 papers were not travel writing. They were a natural experiment with a clean split: circulating testosterone stayed in range, DHT did not, and the tissues that need DHT stayed small. External genitalia and the prostate depend on that conversion before birth and in early infancy. Without it, newborns look female or ambiguous. Puberty later floods the system with testosterone, which is enough to push much of male maturation through - late, and never quite complete. Villagers had already named the delay. The papers named the enzyme. That order still governs the file.
James Hamilton had already shown, in 1947, that men without testicular androgens do not go bald in the usual pattern. Imperato-McGinley added the missing enzyme name. Baldness and prostate growth were not 'male hormone' in the vague sense. They were DHT-amplified jobs. Once that sentence exists, a drug company can ask a practical question: can an adult take a reversible version of the gap without undoing anatomy that already finished decades earlier?
The jobs DHT keeps that testosterone does not
File this split before you read any later milligram: testosterone carries most of what people mean by male function. DHT is a local amplifier in a short list of tissues.
DHT drives external genital formation and prostate budding in fetal life. It also miniaturises genetically vulnerable scalp follicles over years. Acne and a receding hairline were rare in the enzyme-deficient men, even with normal testosterone. Muscle, sperm production, and much of adult drive still ran on the parent hormone. That is why a selective type 2 blocker can shrink a gland and slow a hairline without flattening every androgen effect in the body.
Selective is not the same as silent. Type 2 5-alpha-reductase sits in prostate, genital skin, and the outer root sheath of follicles. Type 1 lives more in sebaceous skin. Finasteride hits type 2 hard and type 1 weakly. Dutasteride later blocked both. The history file only needs this: Merck copied the isoform the children lacked. Every later argument about sexual signals, PSA, and hair density still hangs on that one lever. How the lever is used at 1 mg versus 5 mg is a different article - the 1 mg versus 5 mg evidence file.
Merck set out to copy a missing enzyme
Roy Vagelos's group at Merck treated the Dominican phenotype as a design brief. Induce the enzyme gap in a healthy adult. Keep it reversible. Do not touch fetal development that already finished. Chemists landed on finasteride, a synthetic 4-azasteroid that competitively inhibits type 2 5-alpha-reductase and does not bind the androgen receptor. It is not an anti-androgen in the receptor sense. It is a conversion brake.
Pharmacology matched the field note with unusual cleanliness. Circulating DHT falls about 65 percent within 24 hours of a 1 mg tablet. Testosterone stays near baseline or rises slightly as the conversion stall backs up the parent hormone. Plasma half-life is short - about 5 to 6 hours in men under 60, nearer 8 hours after 70 - yet enzyme blockade outlasts the blood level, which is why once-daily dosing works. Bioavailability of the 1 mg tablet averages about 65 percent and food does not matter. Those numbers sit on the Propecia 1 mg fact line. The history point is simpler: the molecule was built to impersonate a genetic state, not to invent a new one.
The 5 mg prostate tablet had to ship first
Strike the hair-first myth. The first approved job was an enlarged gland, because that is where the natural experiment pointed with the hardest clinical need.
An aging prostate keeps growing under DHT. The urethra narrows. Men get a weak stream, hesitancy, frequency, and night walking. Surgery was the main answer before 1992. If men born without the enzyme kept small glands, a pill that lowered DHT should shrink an overgrown one. Merck filed Proscar, finasteride 5 mg, and the FDA cleared it on 19 June 1992 for symptomatic benign prostatic hyperplasia - the first 5-alpha-reductase inhibitor on a US label.
Benefit was real and slow. Volume drops over months, not days. Later four-year work (PLESS) added the endpoints that change practice: fewer acute retention events and fewer operations. Those numbers belong in the evidence file, not here. What the history file keeps is sequence. Hair was a footnote inside a urology program until someone noticed that a much smaller daily dose still moved scalp counts.
How a 1 mg hair line grew out of a gland program
Male-pattern thinning is DHT acting on follicles that are genetically set to miniaturise. Cut the amplifier and you brake the shrink, sometimes enough to thicken a crown. Prostate trial men, and the original enzyme-deficient adults, had already hinted at that. Merck ran hair-specific studies in men aged 18 to 41 with early vertex or mid-scalp loss and found the scalp answered at 1 mg daily - one-fifth of the Proscar strength - because type 2 in the follicle saturates early.
Propecia, finasteride 1 mg, was approved on 22 December 1997 for male-pattern hair loss in men only. Same compound. Same enzyme. Different tissue, different milligrams, different name. It was the first oral agent with randomised photo and count evidence for slowing genetic balding. It is contraindicated in women who are or may become pregnant. It is not a cure. Stop the tablet and DHT returns, and the hair line walks back. Practical limits and the sexual-signal row sit in the 1 mg cost and honesty guide.
File the arc: one lever, two later labels
1947
James Hamilton links testicular androgens to common male balding after studying men with testicular insufficiency.
1974
Julianne Imperato-McGinley reports Dominican children with type 2 5-alpha-reductase deficiency, low DHT, small prostates, and no pattern baldness.
Early 1980s
Merck, under Roy Vagelos, builds finasteride as a reversible type 2 copy of that enzyme gap.
19 June 1992
FDA clears Proscar, finasteride 5 mg, for symptomatic BPH - first drug in the class.
22 Dec 1997
FDA clears Propecia, finasteride 1 mg, for male-pattern hair loss in men only.
2003
PCPT reports fewer overall prostate cancers on 5 mg, with a debated high-grade excess.
Zoom out and finasteride is one of the few widely used tablets whose label logic was read almost straight from human genetics. A field endocrinologist saw that children missing one enzyme reached adulthood with tiny prostates and intact hairlines. A company built a reversible copy. Both later indications - gland shrinkage and scalp hold - were visible in that first clinic note years before either bottle shipped. That is rare. Most first-in-class stories wander. This one did not.
The arc also sets the honesty bar. The drug does one thing: block type 2 5-alpha-reductase and lower DHT. Every benefit and every complaint flows from that lever. It is not a miracle hair reset and it is not a free lunch. Sexual-signal questions, the 2012 persistence add on the label, and the PSA half-cut all belong to that same biochemistry. Dispute the numbers if you want. Do not dispute the origin. The 5-alpha story is the file, not the marketing. Keep the dates: 1974 named the enzyme, 1992 bottled the gland, 1997 bottled the hair line.
Reader mail
Reader questions on this article
Answered by Dr. Priya Anand, MD · Urology & men's health
Readers sent origin claims after this 5-alpha file went up. These answers strike the folklore and keep the dates.
Real case series, published, not campfire copy. Julianne Imperato-McGinley reported these children in the 1970s. The diagnosis - type 2 5-alpha-reductase deficiency - is a recognised genetic disorder, also described in other isolated groups, including parts of Papua New Guinea. Affected children make testosterone and convert too little of it to DHT, so external genital development lags until puberty. Guevedoces is local language. The endocrine data are the file. That work pointed Merck at the enzyme. Hormone basics in plain language sit at MedlinePlus.
Why does blocking DHT help a prostate and a hairline without wrecking every male function?
Because the two androgens split the work. Testosterone carries most of drive, muscle, and sperm. DHT is a local amplifier in prostate and in follicles that are genetically set to shrink. The enzyme-deficient adults made the split obvious: small glands, almost no balding, otherwise male puberty. Finasteride drops circulating DHT by about 65 percent while testosterone stays near baseline. That is the design. It is not a mute button on every androgen, which is why most men keep systemic function - and why a minority still notice a sexual-signal change. Selectivity is the point. Absolute silence is not.
If Proscar and Propecia are the same molecule, why two names and two strengths?
Branding and anatomy, not two drugs. Both tablets are finasteride. Proscar is 5 mg, cleared 19 June 1992 for an enlarged prostate, where you want gland suppression. Propecia is 1 mg, cleared 22 December 1997 for hair loss, because follicle type 2 saturates near that daily dose. Separate names tracked different clinics, prices, and habits. Some men on 5 mg for BPH notice thicker hair. Same lever, higher exposure. Do not treat the names as different chemistry. Treat them as different jobs. The milligram split is unpacked in the 1 mg versus 5 mg evidence file.
Did Merck really design this backwards from a genetic condition?
In the broad strokes, yes. Typical pipelines screen huge libraries and hope. Finasteride started with a crisp human observation: people lacking type 2 5-alpha-reductase kept small prostates and full hairlines with few other adult deficits. That named the enzyme and forecast the phenotype. Chemists then set out to mimic the gap in adults, safely and reversibly. Biology supplied the target. The lab followed. That is why clinical effects matched prediction more cleanly than most first-in-class stories. It is also why every later safety argument still traces to one conversion step.
Those children lacked the enzyme from birth. Is swallowing finasteride the same state?
No, and the distinction is the whole safety file. Those children never made adequate enzyme during fetal life, which is why external genitals formed atypically before birth. An adult who starts a tablet already has finished anatomy. Lowering DHT now cannot undo development completed decades earlier. What the pill reproduces is the ongoing piece: less DHT hitting prostate and scalp from this point forward. The sharp exception is pregnancy. A developing male fetus still needs DHT, so women who are or may become pregnant must not handle crushed tablets. For an adult man the risk profile is a different conversation.
How fast does DHT actually fall, and why does the mirror lag?
At 1 mg, circulating DHT falls about 65 percent, usually within a day. The 5 mg prostate dose does not buy a much deeper serum drop because the enzyme is largely saturated at 1 mg. Extra milligrams buy more gland effect than more scalp effect. Biochemistry is fast. Visible change is not. Follicles cycle over months. A prostate needs months to shrink. Expect the lab value to move in days and the mirror or the stream to lag by three to six months, often longer. Judging a 1 mg hair pill at week three is reading the wrong clock.
Is this an old, settled drug or is the science still moving?
Core pharmacology has been stable since the 1990s. Tens of millions of prescriptions map the main benefits and the common adverse effects. What stays contested is the fringe: whether a subset keeps sexual or mood symptoms after the last dose - the post-finasteride reports - and how to read the high-grade cancer signal from prevention trials. Those are open questions, not slogans. Current US labelling and safety notices live at the FDA. Use primary pages, not forum stacks, when you want the file rather than the noise.
Who was James Hamilton, and why does 1947 belong on this timeline?
Hamilton was a Yale anatomist who studied men with testicular insufficiency and showed that common male balding needs testicular androgens. Without that earlier observation, the Dominican enzyme gap would have been a genital curiosity. With it, Imperato-McGinley could say: the androgen that matters for the hairline is the converted one, DHT, not testosterone in bulk. Merck then had a two-step brief - block the conversion, spare the parent hormone. 1947 is the first strike on the vague 'male hormone' claim. 1974 is the enzyme name. 1992 and 1997 are the bottles.
Why should a hair-line reader care about a 1970s village at all?
Because every later argument you will hear - miracle reset, hidden castration, 'just a vanity pill' - is a fight about that one enzyme. If you know the 5-alpha story, you already know what the tablet can and cannot do. It will not rebuild a dead follicle. It will not flatten every androgen in the body. It will lower DHT while you swallow it, and it will stop doing that when you quit. The village is not colour. It is the reason the label has two strengths and one contraindication that never bends around pregnancy. That is the file I want a reader to keep.
General education from a clinician, not personal medical advice. Bring your own history to your own prescriber.
Last Updated